https://www.selleckchem.com/pr....oducts/upadacitinib.
The VE-BASKET and ROAR basket trials explored the efficacy of vemurafenib and the combination of dabrafenib/trametinib, respectively, in BRAF V600 mutation-positive cancers other than melanoma, papillary thyroid cancer, colorectal cancer and non small cell lung cancer. Within the concept of tumor type agnostic therapy, we decided to treat our BRAF-mutated tumors with the association of BRAF and MEK inhibitors. Our results confirm the emerging importance of molecular tumor profiling for the successful management of cancer, and the p
Synes godt om
Kommentar
Del
